Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS safety_alert · 2013-10-16

Clinical Trial Update: Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating renal toxicity risk of iodixanol and iopromide in patients with chronic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ULTRAVIST (IOPROMIDE)
  • VISIPAQUE (IODIXANOL)

Snippet

Sponsor: Yong Huo | Conditions: Kidney Failure, Chronic | Phase 4 | Status: UNKNOWN